ST 503
Alternative Names: ST-503Latest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator Sangamo Therapeutics
- Class Analgesics; Gene therapies; Zinc finger DNA binding proteins
- Mechanism of Action NAV1.7 voltage gated sodium channel expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neuropathic pain
Most Recent Events
- 19 Nov 2024 Preclinical trials in Neuropathic pain in USA (Intrathecal) prior to November 2024
- 19 Nov 2024 US FDA approves IND application for ST 503 for the treatment of intractable pain due to idiopathic small fiber neuropathy
- 19 Nov 2024 Pharmacodynamics and adverse event data from the preclinical trial in Neuropathic pain released by Sangamo Therapeutics